COMPANY

Aronora

HQ: Portland, OR source · aronora.com ↗ · West Coast

Past trials only

Location: Portland, OR · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Thrombosis myocardial ischemia sepsis End Stage Renal Disease osteoarthritis ischemic stroke AB002

4Trials (company is sponsor)49NIH grants

Funding and NIH signals

NIH award NIH awarded $1.07M (SBIR Phase II 5R44HL170881-03, continuation, notice Jun 1, 2026). NIH RePORTER 5R44HL170881-03 (Jun 1, 2026)
Evidence (1 event)
- Jun 1, 2026 · NIH RePORTER 5R44HL170881-03
  Organization: ARONORA, INC.; City/State: Portland, OR; Project number: 5R44HL170881-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 1069527; Administering IC: National Heart Lung and Blood Institute; Project title: Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 3, 2019 Trial start Phase 2: Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis source ↗
Oct 29, 2018 Trial start Phase 2: Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis source ↗
May 30, 2018 Trial start Phase 1: Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects source ↗
Jun 5, 2017 Trial start Phase 1: Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT03963895	Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis	Phase 2	Completed	Jul 3, 2019	Dec 29, 2020 (actual)
NCT03612856	Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis	Phase 2	Completed	Oct 29, 2018	Jul 6, 2019 (actual)
NCT03453060	Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects	Phase 1	Completed	May 30, 2018	Nov 25, 2018 (actual)
NCT03097341	Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects	Phase 1	Completed	Jun 5, 2017	Jan 16, 2018 (actual)

NIH awards 49

Annual award amounts. Total $40.4M.

Jun 1, 2026 NIH award 5R44HL170881-03 FY2026: $1,069,527 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Cathete source ↗
Jul 23, 2025 NIH award 5R44HL167467-03 FY2025: $1,331,056 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Vascula source ↗
Jul 18, 2025 NIH award 4R44HL170881-02 FY2025: $1,069,527 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Cathete source ↗
Jun 27, 2024 NIH award 5R44HL162386-03 FY2024: $669,111 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Thrombopoietin Targeting in Myeloproliferative source ↗
Jun 19, 2024 NIH award 4R44HL167467-02 FY2024: $1,480,856 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Vascula source ↗
Jun 6, 2024 NIH award 1R44HL170881-01A1 FY2024: $493,999 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Cathete source ↗
Jun 25, 2023 NIH award 4R44HL162386-02 FY2023: $700,302 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Thrombopoietin Targeting in Myeloproliferative source ↗
May 24, 2023 NIH award 1R44HL167467-01 FY2023: $998,549 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Contact Pathway Inhibitor to Prevent Vascular source ↗
May 9, 2023 NIH award 5R44HL147695-05 FY2023: $999,415 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Antithrombotic Protein C Activator for Hemodialysi source ↗
May 20, 2022 NIH award 5R44HL126235-06 FY2022: $953,492 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Factor XII Inhibitor for Surface Initiated Thrombo source ↗
Apr 30, 2022 NIH award 5R44HL147695-04 FY2022: $999,415 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Antithrombotic Protein C Activator for Hemodialysi source ↗
Apr 22, 2022 NIH award 1R44HL162386-01A1 FY2022: $301,788 awarded for that fiscal year; activity R44 (SBIR); PI LORENTZ, CHRISTINA U; recipient as written: ARONORA, INC., Portland, OR. Thrombopoietin Targeting in Myeloproliferati source ↗
May 19, 2021 NIH award 5R44HL126235-05 FY2021: $981,954 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Factor XII Inhibitor for Surface Initiated Thrombo source ↗
Mar 26, 2021 NIH award 2R44HL147695-03 FY2021: $998,345 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Antithrombotic Protein C Activator for Hemodialysi source ↗
May 22, 2020 NIH award 2R44HL126235-04A1 FY2020: $999,930 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Factor XII Inhibitor for Surface Initiated Throm source ↗
May 15, 2020 NIH award 1R43AR077473-01 FY2020: $224,997 awarded for that fiscal year; activity R43 (SBIR); PI MARKWAY, BRANDON D; recipient as written: ARONORA, INC., Portland, OR. E-WE thrombin for prevention of post-traumatic o source ↗
May 6, 2020 NIH award 5R44HL147695-02 FY2020: $1,493,466 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Antithrombotic Protein C Activator for Hemodialy source ↗
Jul 22, 2019 NIH award 5R44HL106919-06 FY2019: $999,525 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Factor XI inhibitor for thrombosis source ↗
May 13, 2019 NIH award 1R44HL147695-01 FY2019: $994,097 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Antithrombotic Protein C Activator for Hemodialysi source ↗
Mar 15, 2019 NIH award 5R44HL117589-06 FY2019: $998,750 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic Protein C Activator for Myocardial Isc source ↗
Jul 5, 2018 NIH award 2R44HL106919-05 FY2018: $999,525 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Factor XI inhibitor for thrombosis source ↗
Jun 18, 2018 NIH award 5R44HL126235-03 FY2018: $963,088 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. HLS- Factor XII Inhibitor for Surface Initiated Th source ↗
Mar 29, 2018 NIH award 5R44HL117589-05 FY2018: $999,263 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic Protein C Activator for Myocardial Isc source ↗
Sep 13, 2017 NIH award 3R44HL128016-06S1 FY2017: $359,659 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic factor XI blockade for sepsis source ↗
Jul 20, 2017 NIH award 5R44HL126235-02 FY2017: $998,771 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. HLS- Factor XII Inhibitor for Surface Initiated Th source ↗
May 8, 2017 NIH award 2R44HL117589-04 FY2017: $998,107 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic Protein C Activator for Myocardial Isc source ↗
Jul 31, 2016 NIH award 1R44HL126235-01A1 FY2016: $299,563 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. HLS- Factor XII Inhibitor for Surface Initiated source ↗
Jun 16, 2016 NIH award 5R44HL095315-07 FY2016: $872,549 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic Thrombin Analogs source ↗
Apr 9, 2016 NIH award 5R44HL128016-06 FY2016: $997,083 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, ERIK IAN; recipient as written: ARONORA, INC., Portland, OR. Therapeutic factor XI blockade for sepsis source ↗
Jul 24, 2015 NIH award 3R44HL117589-03S1 FY2015: $5,000 awarded for that fiscal year; activity R44 (SBIR); PI VERBOUT, NORAH; recipient as written: ARONORA, INC., Portland, OR. Therapeutic Protein C Activator for Myocardial Ische source ↗